Several anticancer drugs have E6 suppressant effects based on in vitro studies, including vorinostat and mitomycin C. Vorinostat functions as a competitive inhibitor at the E6 binding site of p53, while also downregulating the E6 protein itself in HPV-positive cervical cancer cells. This evidence concerns the gene TP53 and cervical cancer.